A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer
Abstract A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFα on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFα-doubly surface-modified vacc...
Saved in:
Published in | Vaccine Vol. 28; no. 31; pp. 4937 - 4944 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ltd
01.07.2010
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFα on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFα-doubly surface-modified vaccine significantly extended the survival in the orthotopic model of RM-1 prostate cancer, and was superior to single GM-CSF- or TNFα-surface-modified vaccine. Moreover, the splenocytes from the GM-CSF/TNFα-vaccine-treated mice showed the most potent cytotoxicity on RM-1 cells and the highest production of RM-1-specific IFNγ. In addition, more CD4+ and CD8+ T cells infiltrated into the tumor sites in the GM-CSF/TNFα-vaccine-treated mice than in the GM-CSF- or TNFα-vaccine-treated mice. Therefore, our study demonstrated that the efficacy of RM-1 prostate cancer cell vaccine could be improved by conjugating both GM-CSF and TNFα simultaneously on the surface of cancer cells, and that this modification thus has a potential translational significance. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2010.05.038 |